MedTrace Logo

Tamsulosin and the Risk of Serious Adverse Events

NCT07274228 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 14000

Last updated 2026-01-28

No results posted yet for this study

Summary

This is a population-based cohort study assessing whether initiating a higher dose of tamsulosin (0.8 mg/day) compared to a lower dose (0.4 mg/day) in older adults with advanced chronic kidney disease (CKD) (an estimated glomerular filtration rate (eGFR) \<45 mL/min per 1.73 m² but not receiving dialysis or having a history of kidney transplantation) is associated with a higher 90-day risk of a composite outcome of all-cause hospitalization or all-cause emergency visits or all-cause mortality.

Conditions

  • Chronic Kidney Disease (CKD)

Interventions

DRUG

Tamsulosin

The primary exposure of interest will be oral tamsulosin at a dose of 0.4 mg/day, representing the median dose in high-throughput computing analyses. For the primary comparison, oral tamsulosin at a dose of 0.4 mg/day will be chosen to reduce the influence of indication bias.

Sponsors & Collaborators

  • London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

    lead OTHER

Principal Investigators

  • Amit Garg · London Health Sciences Centre Research Institute

Eligibility

Min Age
66 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-01
Primary Completion
2024-12-01
Completion
2025-03-01

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07274228 on ClinicalTrials.gov